REGENXBIO to Present at Two High-Profile Healthcare Conferences
Event summary
- REGENXBIO to participate in Baird 2026 Global Healthcare Conference on September 15.
- Company scheduled for Morgan Stanley 24th Annual Global Healthcare Conference on September 16.
- Live webcasts available via REGENXBIO's investor relations page.
- Archived replays accessible for 30 days post-event.
The big picture
REGENXBIO's participation in back-to-back investor conferences underscores its push to engage with key stakeholders amid a competitive landscape in gene therapy. The company's late-stage pipeline and strategic partnerships position it as a notable player, but execution on clinical milestones will be critical for maintaining momentum. The events provide a platform to address both progress and challenges in delivering curative treatments for rare and retinal diseases.
What we're watching
- Pipeline Progress
- How updates on RGX-202, RGX-121, and RGX-111 will impact investor sentiment.
- Partnership Dynamics
- Whether collaborations with Nippon Shinyaku and AbbVie will be highlighted as growth drivers.
- Market Positioning
- The pace at which REGENXBIO can differentiate itself in the competitive gene therapy space.
Related topics